Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels.
Kv1.5 channels conduct the ultrarapid delayed rectifier current (IKur) that contributes to action potential repolarization of human atrial myocytes. Block of these channels has been proposed as a treatment for atrial arrhythmias. Here we report a novel and potent inhibitor of Kv1.5 potassium channels, N-benzyl-N-pyridin-3-yl-methyl-2-(toluene-4-sulfonylamino)-benzamide hydrochloride (S0100176), which exhibits features consistent with preferential block of the open state. The IC50 of S0100176 for Kv1.5 expressed in Xenopus oocytes was 0.7 microm. Ala-scanning mutagenesis within the pore helix and the S6 segment, regions that form the walls of the central cavity, was combined with voltage clamp analysis to identify point mutations that altered drug affinity. This approach identified Thr-479, Thr-480, Val-505, Ile-508, and Val-512 as the most important residues for block by S0100176. Mutations of these key residues to Ala or other amino acids caused marked changes in the IC50 of S0100176 (p<0.01). For example, the IC50 of S0100176 increased 362-fold for T480A, 26-fold for V505A, 150-fold for I508A, and 99-fold for V512A. We used modeling to dock S0100176 into the inner cavity of a Kv1.5 pore homology model that was generated based on the crystal structure of KcsA. The docking predicted that the five residues identified by the Ala scan were positioned less than 4.5 A from the compound. Based on the homology models, the positions of the five amino acids identified to interact with S0100176 face toward the central cavity and overlap with putative binding sites for other blockers and voltage-gated potassium channels.
University of Utah, Department of Physiology, Eccles Institute of Human Genetics, Salt Lake City, Utah 84112, USA. Niels.decher@hmbg.utah.edu
Niels
N
Decher
Bernard
B
Pirard
Florian
F
Bundis
Stefan
S
Peukert
Karl-Heinz
KH
Baringhaus
Andreas E
AE
Busch
Klaus
K
Steinmeyer
Michael C
MC
Sanguinetti
D019943:Amino Acid Substitution; D000818:Animals; D001665:Binding Sites; D006801:Humans; D051666:Kv1.5 Potassium Channel; D008564:Membrane Potentials / Q000187:drug effects; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D009865:Oocytes; D026902:Potassium Channel Blockers / Q000494:pharmacology*; D015221:Potassium Channels / Q000737:chemistry / Q000187:drug effects / Q000502:physiology; D024642:Potassium Channels, Voltage-Gated / Q000737:chemistry* / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D011487:Protein Conformation; D017433:Protein Structure, Secondary; D011994:Recombinant Proteins / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology*; D014982:Xenopus laevis; D062367:ortho-Aminobenzoates / Q000494:pharmacology*
C496981:KCNA5 protein, human; D051666:Kv1.5 Potassium Channel; C482077:N-benzyl-N-pyridin-3-ylmethyl-2-(toluene-4-sulfonylamino)benzamide; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D011994:Recombinant Proteins; D013449:Sulfonamides; D062367:ortho-Aminobenzoates